Double Hit Diffused Large B Cell Lymphoma and DA-EPOCH-R Regimen - 1290717

Hi Semone, Welcome back to Grace. I know you don't want to be here but glad you have someplace to come back to when needed. Glad to hear your mom is stable. I'm sorry to hear about your husband's diagnosis. It sounds as though he is getting appropriate care even though the classification is pretty new and the standard of treatment is as well.

Following is from an article at ASCO Post on the subject written by Jonathon B. Cohen, MD of Emory Univ. He substantiates the dose adjusted R-EPOCH regimen with good survival rates. Certainly much higher than anything we see in lung cancer.

"The study on which he bases this preference, which was led by the National Cancer Institute, evaluated dose-adjusted R-EPOCH and found that progression-free survival at 14 months was 79% for all MYC-positive patients with non-Hodgkin lymphoma and 87% for the double-hit patients.2 Since newly diagnosed patients had to be stable enough to await the results of the fluorescent in situ hybridization assessment at the time of diagnosis, it is likely that very sick patients were not enrolled." http://www.ascopost.com/issues/september-25-2015/double-hit-lymphoma-ma…

I hope this helps put things into prospective and I'll keep you husband in my thoughts.

All best,
Janine

Hi Semone, Welcome back to Grace. I know you don't want to be here but glad you have someplace to come back to when needed. Glad to hear your mom is stable. I'm sorry to hear about your husband's diagnosis. It sounds as though he is getting appropriate care even though the classification is pretty new and the standard of treatment is as well.

Following is from an article at ASCO Posts on the subject written by Jonathon B. Cohen, MD of Emory Univ. He substantiates the dose adjusted R-EPOCH regimen with good survival rates. Certainly much higher than anything we see in lung cancer.

"The study on which he bases this preference, which was led by the National Cancer Institute, evaluated dose-adjusted R-EPOCH and found that progression-free survival at 14 months was 79% for all MYC-positive patients with non-Hodgkin lymphoma and 87% for the double-hit patients.2 Since newly diagnosed patients had to be stable enough to await the results of the fluorescent in situ hybridization assessment at the time of diagnosis, it is likely that very sick patients were not enrolled." http://www.ascopost.com/issues/september-25-2015/double-hit-lymphoma-ma…

I hope this helps put things into prospective and I'll keep you husband in my thoughts.

All best,
Janine